A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Etoricoxib (Primary) ; Diclofenac
  • Indications Musculoskeletal pain; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 12 Sep 2011 Results published in the Current Medical Research and Opinion.
    • 14 Jul 2009 Actual patient number changed from 750 to 761 as reported by ClinicalTrials.gov.
    • 17 Nov 2008 Actual patient number identified as 750 from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top